Literature DB >> 9662395

Identification of the gene responsible for Best macular dystrophy.

K Petrukhin1, M J Koisti, B Bakall, W Li, G Xie, T Marknell, O Sandgren, K Forsman, G Holmgren, S Andreasson, M Vujic, A A Bergen, V McGarty-Dugan, D Figueroa, C P Austin, M L Metzker, C T Caskey, C Wadelius.   

Abstract

Best macular dystrophy (BMD), also known as vitelliform macular dystrophy (VMD2; OMIM 153700), is an autosomal dominant form of macular degeneration characterized by an abnormal accumulation of lipofuscin within and beneath the retinal pigment epithelium cells. In pursuit of the disease gene, we limited the minimum genetic region by recombination breakpoint analysis and mapped to this region a novel retina-specific gene (VMD2). Genetic mapping data, identification of five independent disease-specific mutations and expression studies provide evidence that mutations within the candidate gene are a cause of BMD. The 3' UTR of the candidate gene contains a region of antisense complementarity to the 3' UTR of the ferritin heavy-chain gene (FTH1), indicating the possibility of antisense interaction between VMD2 and FTH1 transcripts.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9662395     DOI: 10.1038/915

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  226 in total

1.  Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium.

Authors:  A D Marmorstein; L Y Marmorstein; M Rayborn; X Wang; J G Hollyfield; K Petrukhin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

2.  SOX9, through interaction with microphthalmia-associated transcription factor (MITF) and OTX2, regulates BEST1 expression in the retinal pigment epithelium.

Authors:  Tomohiro Masuda; Noriko Esumi
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

3.  Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster.

Authors:  C Bai; B Connolly; M L Metzker; C A Hilliard; X Liu; V Sandig; A Soderman; S M Galloway; Q Liu; C P Austin; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

4.  Drusen proteome analysis: an approach to the etiology of age-related macular degeneration.

Authors:  John W Crabb; Masaru Miyagi; Xiaorong Gu; Karen Shadrach; Karen A West; Hirokazu Sakaguchi; Motohiro Kamei; Azeem Hasan; Lin Yan; Mary E Rayborn; Robert G Salomon; Joe G Hollyfield
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

Review 5.  Genetic factors of age-related macular degeneration.

Authors:  Jingsheng Tuo; Christine M Bojanowski; Chi-Chao Chan
Journal:  Prog Retin Eye Res       Date:  2004-03       Impact factor: 21.198

6.  Clinical utility gene card for: BEST1-related dystrophies (Bestrophinopathies).

Authors:  Simon C Ramsden; Alice E Davidson; Bart P Leroy; Anthony T Moore; Andrew R Webster; Graeme C M Black; Forbes D C Manson
Journal:  Eur J Hum Genet       Date:  2012-01-11       Impact factor: 4.246

Review 7.  International Union of Basic and Clinical Pharmacology. LXXXV: calcium-activated chloride channels.

Authors:  Fen Huang; Xiuming Wong; Lily Y Jan
Journal:  Pharmacol Rev       Date:  2011-11-16       Impact factor: 25.468

8.  Multimodal fundus imaging in Best vitelliform macular dystrophy.

Authors:  Daniela C Ferrara; Rogério A Costa; Stephen Tsang; Daniela Calucci; Rodrigo Jorge; K Bailey Freund
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04-23       Impact factor: 3.117

9.  Bestrophin expression and function in the human pancreatic duct cell line, CFPAC-1.

Authors:  Laura L Marsey; John P Winpenny
Journal:  J Physiol       Date:  2009-02-23       Impact factor: 5.182

Review 10.  Underdeveloped RPE Apical Domain Underlies Lesion Formation in Canine Bestrophinopathies.

Authors:  Karina E Guziewicz; Emily McTish; Valerie L Dufour; Kathryn Zorych; Anuradha Dhingra; Kathleen Boesze-Battaglia; Gustavo D Aguirre
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.